Sectors & IndustriesHealthcareDrug Manufacturers - General

Best General Drug Manufacturer Stocks to Buy Now (2023)

Top general drug manufacturer stocks in 2023 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 57, which is 16 points higher than the general drug manufacturer industry average of 41. It passed 21 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -15.7% over the past year, underperforming other general drug manufacturer stocks by -45 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $70.75, an upside of 20.36% from Bristol Myers Squibb Co's current stock price of $58.78.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 41.67% have issued a hold, while 8.33% have issued a Sell rating, and 8.33% have issued a Strong Sell.

Horizon Therapeutics Public Co (NASDAQ:HZNP) is the second best general drug manufacturer stock with a Zen Score of 54, which is 13 points higher than the general drug manufacturer industry average of 41. It passed 18 out of 33 due diligence checks and has strong fundamentals. Horizon Therapeutics Public Co has seen its stock return 82.1% over the past year, overperforming other general drug manufacturer stocks by 52 percentage points.

Gilead Sciences (NASDAQ:GILD) is the third best general drug manufacturer stock with a Zen Score of 53, which is 12 points higher than the general drug manufacturer industry average of 41. It passed 19 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 17.4% over the past year, underperforming other general drug manufacturer stocks by -12 percentage points.

Gilead Sciences has an average 1 year price target of $87.67, an upside of 15.63% from Gilead Sciences's current stock price of $75.82.

Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Gilead Sciences, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 44.44% have issued a hold, while 11.11% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

Pfizer (NYSE:PFE) has an annual dividend yield of 4.85%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.06%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 42.8% indicates that its dividend yield is sustainable for the long-term.

Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 3.93%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.06%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 67.4% indicates that its dividend yield is sustainable for the long-term.

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 3.83%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.06%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 59.5% indicates that its dividend yield is sustainable for the long-term.

General drug manufacturer stocks were up 0.42% in the last day, and down -0.31% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

Grifols Sa (NASDAQ:GRFS) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Grifols Sa's stock has gained 14.2% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -15 percentage points.

Organon & Co (NYSE:OGN) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Organon & Co has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -30.7% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -60 percentage points.

Sanofi (NASDAQ:SNY) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Sanofi's stock has gained 38.21% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 9 percentage points.